



Clinical trial results:

A Phase 1b Study to Evaluate SIMPONI® (golimumab) Therapy in Children, Adolescents, and Young Adults with Pre-Symptomatic Type 1 Diabetes

Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2017-000225-12 |
| Trial protocol | SE FI |
| Global end of trial date | 20 December 2020 |

Results information

| | |
|--------------------------------|--------------|
| Result version number | v1 (current) |
| This version publication date | 07 July 2021 |
| First version publication date | 07 July 2021 |

Trial information

Trial identification

| | |
|-----------------------|----------------|
| Sponsor protocol code | CNT0148DML1001 |
|-----------------------|----------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03298542 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Janssen Research and Development, LLC |
| Sponsor organisation address | 920, US Highway, Route 202, South Raritan, United States, 08869 |
| Public contact | Clinical Registry Group, Janssen Research and Development, LLC, ClinicalTrialsEU@its.jnj.com |
| Scientific contact | Clinical Registry Group, Janssen Research and Development, LLC, ClinicalTrialsEU@its.jnj.com |

Notes:

Paediatric regulatory details

| | |
|--|-----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 20 December 2020 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 20 December 2020 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The main objective of this study was to determine the safety and tolerability of golimumab in children, adolescents, and young adults with pre-symptomatic Stage 2 Type 1 diabetes (T1D).

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. Safety evaluations included regular monitoring for clinically related adverse events (AEs), monitoring of clinical laboratory changes (that is hematological and serum chemistry panel) and active monitoring of early detection of active tuberculosis (TB), vital signs and physical examination findings were evaluated. Monitoring of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) viral load was done to detect if there is any study treatment effect on primary immune response to these infections that often take place during childhood and adolescence or could impact reactivation of these viruses in those who have been infected previously.

Background therapy: -

Evidence for comparator: -

| | |
|---|-----------------|
| Actual start date of recruitment | 22 January 2018 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------------|
| Country: Number of subjects enrolled | Finland: 2 |
| Country: Number of subjects enrolled | United States: 6 |
| Worldwide total number of subjects | 8 |
| EEA total number of subjects | 2 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 6 |

| | |
|---------------------------|---|
| Adolescents (12-17 years) | 2 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 21 subjects were screened of which 8 subjects with Stage 2 Type 1 Diabetes (T1D) were enrolled.

Period 1

| | |
|------------------------------|-------------------------------------|
| Period 1 title | Active Treatment Period (Week 0-26) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Carer |

Arms

| | |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes |
| Arm title | Placebo |

Arm description:

Subjects received a subcutaneous (SC) placebo injection every 2 weeks (q2w) through Week 26 to match the active arm.

| | |
|--|-------------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo (for Golimumab) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Subjects received a SC placebo injection q2w through Week 26 to match the active arm.

| | |
|------------------|-----------|
| Arm title | Golimumab |
|------------------|-----------|

Arm description:

Subjects weighing (<) 45 kilograms (kg) received an induction dose of golimumab 60 milligrams per meter square (mg/m²) SC at Weeks 0 and 2 followed by a maintenance dose of 30 mg/m² SC at Week 4 and q2w through Week 26. Participants weighing greater than or equal to (>=) 45 kg received an induction dose of golimumab 100 mg SC at Weeks 0 and 2 followed by a maintenance dose of golimumab 50 mg SC at Week 4 and q2w through Week 26.

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Golimumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Subjects <45 kg received an induction dose of golimumab 60 mg/m² SC at Weeks 0 and 2 followed by a maintenance dose of 30 mg/m² SC at Week 4 and q2w through Week 26. Participants weighing >= 45 kg received an induction dose of golimumab 100 mg SC at Weeks 0 and 2 followed by a maintenance dose of golimumab 50 mg SC at Week 4 and q2w through Week 26.

| Number of subjects in period 1 | Placebo | Golimumab |
|--------------------------------|---------|-----------|
| Started | 3 | 5 |
| Completed | 3 | 5 |

Period 2

| | |
|------------------------------|--|
| Period 2 title | Off-therapy Follow-up Period(Week 26-52) |
| Is this the baseline period? | No |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes |
| Arm title | Placebo |

Arm description:

Following the 26-week active treatment period, participants were monitored for an additional 26 weeks for safety.

| | |
|---|-----------------|
| Arm type | No intervention |
| No investigational medicinal product assigned in this arm | |
| Arm title | Golimumab |

Arm description:

Following the 26-week active treatment period, participants were monitored for an additional 26 weeks for safety.

| | |
|---|-----------------|
| Arm type | No intervention |
| No investigational medicinal product assigned in this arm | |

| Number of subjects in period 2 | Placebo | Golimumab |
|--------------------------------|---------|-----------|
| Started | 3 | 5 |
| Completed | 3 | 5 |

Baseline characteristics

Reporting groups

| | |
|---|-----------|
| Reporting group title | Placebo |
| Reporting group description: | |
| Subjects received a subcutaneous (SC) placebo injection every 2 weeks (q2w) through Week 26 to match the active arm. | |
| Reporting group title | Golimumab |
| Reporting group description: | |
| Subjects weighing (<) 45 kilograms (kg) received an induction dose of golimumab 60 milligrams per meter square (mg/m ²) SC at Weeks 0 and 2 followed by a maintenance dose of 30 mg/m ² SC at Week 4 and q2w through Week 26. Participants weighing greater than or equal to (>=) 45 kg received an induction dose of golimumab 100 mg SC at Weeks 0 and 2 followed by a maintenance dose of golimumab 50 mg SC at Week 4 and q2w through Week 26. | |

| Reporting group values | Placebo | Golimumab | Total |
|---|---------|-----------|-------|
| Number of subjects | 3 | 5 | 8 |
| Title for AgeCategorical Units: subjects | | | |
| Children (2-11 years) | 2 | 3 | 5 |
| Adolescents (12-17 years) | 1 | 2 | 3 |
| Adults (18-64 years) | 0 | 0 | 0 |
| From 65 to 84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Title for AgeContinuous Units: years | | | |
| arithmetic mean | 10.04 | 11.08 | |
| standard deviation | ± 1.873 | ± 2.79 | - |
| Title for Gender Units: subjects | | | |
| Female | 1 | 0 | 1 |
| Male | 2 | 5 | 7 |

End points

End points reporting groups

| | |
|---|-----------------|
| Reporting group title | Placebo |
| Reporting group description: Subjects received a subcutaneous (SC) placebo injection every 2 weeks (q2w) through Week 26 to match the active arm. | |
| Reporting group title | Golimumab |
| Reporting group description: Subjects weighing (<) 45 kilograms (kg) received an induction dose of golimumab 60 milligrams per meter square (mg/m ²) SC at Weeks 0 and 2 followed by a maintenance dose of 30 mg/m ² SC at Week 4 and q2w through Week 26. Participants weighing greater than or equal to (>=) 45 kg received an induction dose of golimumab 100 mg SC at Weeks 0 and 2 followed by a maintenance dose of golimumab 50 mg SC at Week 4 and q2w through Week 26. | |
| Reporting group title | Placebo |
| Reporting group description: Following the 26-week active treatment period, participants were monitored for an additional 26 weeks for safety. | |
| Reporting group title | Golimumab |
| Reporting group description: Following the 26-week active treatment period, participants were monitored for an additional 26 weeks for safety. | |
| Subject analysis set title | Placebo |
| Subject analysis set type | Safety analysis |
| Subject analysis set description: Subjects who received at least 1 dose of study agent. | |
| Subject analysis set title | Golimumab |
| Subject analysis set type | Safety analysis |
| Subject analysis set description: Subjects who received at least 1 dose of study agent. | |

Primary: Percentage of Subjects with Treatment-emergent Adverse Events (TEAEs) Up to Week 26

| | |
|--|--|
| End point title | Percentage of Subjects with Treatment-emergent Adverse Events (TEAEs) Up to Week 26 ^[1] |
| End point description: An adverse event (AE) was defined as any untoward medical occurrence in clinical study subject administered medicinal product. It could be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product. Treatment emergent AEs were defined as AEs with onset during the treatment phase or that are a consequence of a pre-existing condition that has worsened since baseline. Safety analysis set included all subjects who had received at least 1 dose of study agent. | |
| End point type | Primary |
| End point timeframe: Up to Week 26 | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics was done, no inferential statistical analysis was performed.

| End point values | Placebo | Golimumab | | |
|-------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3 | 5 | | |
| Units: percentage of subjects | | | | |
| number (not applicable) | 100 | 100 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects with Treatment-emergent Serious Adverse Events (SAEs) Up to Week 26

| | |
|-----------------|---|
| End point title | Percentage of Subjects with Treatment-emergent Serious Adverse Events (SAEs) Up to Week 26 ^[2] |
|-----------------|---|

End point description:

An AE was defined as any untoward medical occurrence in clinical study subject administered medicinal product. It could be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product. A SAE was defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious treatment via medicinal product and was medically important. Safety analysis set included all subjects who had received at least 1 dose of study agent.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to Week 26

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics was done, no inferential statistical analysis was performed.

| End point values | Placebo | Golimumab | | |
|-------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3 | 5 | | |
| Units: percentage of subjects | | | | |
| number (not applicable) | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects with Treatment-emergent AEs Up to Week 52

| | |
|-----------------|---|
| End point title | Percentage of Subjects with Treatment-emergent AEs Up to Week 52 ^[3] |
|-----------------|---|

End point description:

An adverse event (AE) was defined as any untoward medical occurrence in clinical study subject administered medicinal product. It could be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product. Treatment emergent AEs were defined as AEs with onset during the treatment phase or that are a consequence of a pre-existing condition that has worsened since baseline.

Safety analysis set included all subjects who had received at least 1 dose of study agent.

| | |
|----------------------|---------|
| End point type | Primary |
| End point timeframe: | |
| Up to Week 52 | |

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics was done, no inferential statistical analysis was performed.

| End point values | Placebo | Golimumab | | |
|-------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 3 | 5 | | |
| Units: percentage of subjects | | | | |
| number (not applicable) | 100 | 100 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects with Treatment-emergent SAEs Up to Week 52

| | |
|-----------------|--|
| End point title | Percentage of Subjects with Treatment-emergent SAEs Up to Week 52 ^[4] |
|-----------------|--|

End point description:

An AE was defined as any untoward medical occurrence in clinical study subject administered medicinal product. It could be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product. A SAE was defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious treatment via medicinal product and was medically important. Safety analysis set included all subjects who had received at least 1 dose of study agent.

| | |
|----------------------|---------|
| End point type | Primary |
| End point timeframe: | |
| Up to Week 52 | |

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics was done, no inferential statistical analysis was performed.

| End point values | Placebo | Golimumab | | |
|-------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 3 | 5 | | |
| Units: percentage of subjects | | | | |
| number (not applicable) | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects with Treatment-emergent Infections Up to Week 26

| | |
|-----------------|--|
| End point title | Percentage of Subjects with Treatment-emergent Infections Up to Week 26 ^[5] |
|-----------------|--|

End point description:

Subjects who had developed non-severe infections such as influenza, upper respiratory tract infection, rhinitis, nasopharyngitis, otitis externa (active), and gastroenteritis were reported. The safety analysis set included all subjects who had received at least 1 dose of study agent.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to Week 26

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics was done, no inferential statistical analysis was performed.

| End point values | Placebo | Golimumab | | |
|-------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3 | 5 | | |
| Units: percentage of subjects | | | | |
| number (not applicable) | 100 | 60 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects with Treatment-emergent Infections Up to Week 52

| | |
|-----------------|--|
| End point title | Percentage of Subjects with Treatment-emergent Infections Up to Week 52 ^[6] |
|-----------------|--|

End point description:

Subjects who had developed non-severe infections such as influenza, upper respiratory tract infection, rhinitis, nasopharyngitis, otitis externa (active), and gastroenteritis were reported. The safety analysis set included all subjects who had received at least 1 dose of study agent.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to Week 52

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics was done, no inferential statistical analysis was performed.

| End point values | Placebo | Golimumab | | |
|-------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 3 | 5 | | |
| Units: percentage of subjects | | | | |
| number (not applicable) | 100 | 60 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects with Study Treatment Injection Site Reactions

| | |
|-----------------|---|
| End point title | Percentage of Subjects with Study Treatment Injection Site Reactions ^[7] |
|-----------------|---|

End point description:

An injection site reaction was any unfavorable or unintended sign that occurred at the study agent injection site. If an injection site reaction was observed, the participant was treated at the investigator's discretion. The safety analysis set included all subjects who had received at least 1 dose of study agent.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to Week 52

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics was done, no inferential statistical analysis was performed.

| End point values | Placebo | Golimumab | | |
|-------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 3 | 5 | | |
| Units: percentage of subjects | | | | |
| number (not applicable) | 0 | 40 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Serum Concentrations of Golimumab

| | |
|-----------------|--|
| End point title | Serum Concentrations of Golimumab ^[8] |
|-----------------|--|

End point description:

Serum samples for the measurement of golimumab concentrations were collected at Weeks 0, 2, 4, 8, 12, and 26. Samples at Week 0, 2, and 4 were associated with the induction doses administered at Weeks 0 and 2. Pharmacokinetics (PK) analysis set included 5 subjects who received at least 1 golimumab injection and had sufficient PK samples for analysis. Here 'n' (number analyzed) included all subjects who were analyzed at specified timepoints.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Weeks 0, 2, 4, 8, 12 and 26

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint was planned to be analyzed for specified arms only.

| End point values | Golimumab | | | |
|--|-----------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 5 | | | |
| Units: micrograms per milliliter (µg/mL) | | | | |
| arithmetic mean (standard deviation) | | | | |
| Week 0: Preinjection (n=5) | 0 (± 0) | | | |

| | | | | |
|-----------------------------|----------------|--|--|--|
| Week 2: Preinjection (n=4) | 5.09 (± 1.351) | | | |
| Week 4: Preinjection (n=5) | 9.01 (± 2.78) | | | |
| Week 8: Preinjection (n=5) | 5.09 (± 2.211) | | | |
| Week 12: Preinjection (n=5) | 4.52 (± 2.404) | | | |
| Week 26: Preinjection (n=5) | 3.95 (± 2.845) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Antibodies to Golimumab

| | |
|-----------------|--|
| End point title | Number of Subjects with Antibodies to Golimumab ^[9] |
|-----------------|--|

End point description:

Number of subjects with antibodies to golimumab were reported. Full Analysis Set included all subjects who received at least 1 dose of golimumab and had appropriate samples for detection of antibodies to golimumab.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Week 26

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint was planned to be analyzed for specified arms only.

| | | | | |
|-----------------------------|-----------------|--|--|--|
| End point values | Golimumab | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 5 | | | |
| Units: subjects | 2 | | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to Week 52

Adverse event reporting additional description:

The safety analysis set included all subjects who had received at least 1 dose of study agent.

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 23.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|-----------------------|
| Reporting group title | Placebo (Week 0 - 26) |
|-----------------------|-----------------------|

Reporting group description:

Subjects received a SC placebo injection q2w through Week 26 to match the active arm.

| | |
|-----------------------|-------------------------|
| Reporting group title | Golimumab (Week 0 - 26) |
|-----------------------|-------------------------|

Reporting group description:

Subjects <45 kg received an induction dose of golimumab 60 mg/m² SC at Weeks 0 and 2 followed by a maintenance dose of 30 mg/m² SC at Week 4 and q2w through Week 26. Participants weighing ≥ 45 kg received an induction dose of golimumab 100 mg SC at Weeks 0 and 2 followed by a maintenance dose of golimumab 50 mg SC at Week 4 and q2w through Week 26.

| | |
|-----------------------|------------------------|
| Reporting group title | Placebo (Week 26 - 52) |
|-----------------------|------------------------|

Reporting group description:

Following the 26-week active treatment period, participants were monitored for an additional 26 weeks for safety.

| | |
|-----------------------|--------------------------|
| Reporting group title | Golimumab (Week 26 - 52) |
|-----------------------|--------------------------|

Reporting group description:

Following the 26-week active treatment period, participants were monitored for an additional 26 weeks for safety.

| Serious adverse events | Placebo (Week 0 - 26) | Golimumab (Week 0 - 26) | Placebo (Week 26 - 52) |
|---|-----------------------|-------------------------|------------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 5 (0.00%) | 0 / 3 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |

| Serious adverse events | Golimumab (Week 26 - 52) | | |
|---|--------------------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Placebo (Week 0 - 26) | Golimumab (Week 0 - 26) | Placebo (Week 26 - 52) |
|---|-----------------------|-------------------------|------------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 3 / 3 (100.00%) | 5 / 5 (100.00%) | 3 / 3 (100.00%) |
| General disorders and administration site conditions | | | |
| Injection Site Pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 5 (20.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injection Site Urticaria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 5 (20.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Malaise | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 5 (20.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Immune system disorders | | | |
| Serum Sickness | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 5 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 5 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Nasal Congestion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 5 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oropharyngeal Pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 5 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Investigations | | | |
| Body Temperature Decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 5 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |

| | | | |
|---|---------------------|---------------------|---------------------|
| Head Injury subjects affected / exposed occurrences (all) | 1 / 3 (33.33%) 1 | 0 / 5 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Skin Abrasion subjects affected / exposed occurrences (all) | 1 / 3 (33.33%) 1 | 1 / 5 (20.00%) 1 | 1 / 3 (33.33%) 1 |
| Nervous system disorders Dizziness subjects affected / exposed occurrences (all) | 1 / 3 (33.33%) 1 | 0 / 5 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Headache subjects affected / exposed occurrences (all) | 2 / 3 (66.67%) 3 | 1 / 5 (20.00%) 2 | 1 / 3 (33.33%) 1 |
| Syncope subjects affected / exposed occurrences (all) | 1 / 3 (33.33%) 1 | 0 / 5 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Blood and lymphatic system disorders Neutropenia subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 5 (20.00%) 7 | 0 / 3 (0.00%) 0 |
| Eye disorders Eye Pain subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 5 (20.00%) 1 | 0 / 3 (0.00%) 0 |
| Gastrointestinal disorders Abdominal Pain subjects affected / exposed occurrences (all) | 1 / 3 (33.33%) 1 | 0 / 5 (0.00%) 0 | 0 / 3 (0.00%) 0 |
| Skin and subcutaneous tissue disorders Dermatitis Atopic subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 5 (20.00%) 1 | 0 / 3 (0.00%) 0 |
| Nail Bed Inflammation subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 5 (20.00%) 1 | 0 / 3 (0.00%) 0 |
| Papule | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 5 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pigmentation Disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 5 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 5 (20.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 5 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 5 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 5 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Infections and infestations | | | |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 5 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 5 (20.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 1 | 1 | 1 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 2 / 3 (66.67%) | 1 / 5 (20.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Otitis Externa | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 5 (20.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 5 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Upper Respiratory Tract Infection | | | |

| | | | |
|--|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 1 / 3 (33.33%) 1 | 1 / 5 (20.00%) 1 | 1 / 3 (33.33%) 2 |
| Metabolism and nutrition disorders Type 1 Diabetes Mellitus subjects affected / exposed occurrences (all) | 0 / 3 (0.00%) 0 | 1 / 5 (20.00%) 1 | 0 / 3 (0.00%) 0 |

| | | | |
|---|--|--|--|
| Non-serious adverse events | Golimumab (Week 26 - 52) | | |
| Total subjects affected by non-serious adverse events subjects affected / exposed | 5 / 5 (100.00%) | | |
| General disorders and administration site conditions Injection Site Pain subjects affected / exposed occurrences (all) Injection Site Urticaria subjects affected / exposed occurrences (all) Malaise subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 | | |
| Immune system disorders Serum Sickness subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | | |
| Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) Nasal Congestion subjects affected / exposed occurrences (all) Oropharyngeal Pain subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 1 / 5 (20.00%) 1 1 / 5 (20.00%) 1 | | |
| Investigations | | | |

| | | | |
|--|--|--|--|
| Body Temperature Decreased subjects affected / exposed occurrences (all) | 1 / 5 (20.00%) 1 | | |
| Injury, poisoning and procedural complications Head Injury subjects affected / exposed occurrences (all) Skin Abrasion subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 1 / 5 (20.00%) 2 | | |
| Nervous system disorders Dizziness subjects affected / exposed occurrences (all) Headache subjects affected / exposed occurrences (all) Syncope subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 | | |
| Blood and lymphatic system disorders Neutropenia subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | | |
| Eye disorders Eye Pain subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | | |
| Gastrointestinal disorders Abdominal Pain subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | | |
| Skin and subcutaneous tissue disorders Dermatitis Atopic subjects affected / exposed occurrences (all) Nail Bed Inflammation | 0 / 5 (0.00%) 0 | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 5 (0.00%) | | |
| occurrences (all) | 0 | | |
| Papule | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | | |
| occurrences (all) | 1 | | |
| Pigmentation Disorder | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | | |
| occurrences (all) | 1 | | |
| Rash | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | | |
| occurrences (all) | 0 | | |
| Urticaria | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | | |
| occurrences (all) | 0 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | | |
| occurrences (all) | 0 | | |
| Myalgia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | | |
| occurrences (all) | 0 | | |
| Infections and infestations | | | |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | | |
| occurrences (all) | 0 | | |
| Influenza | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | | |
| occurrences (all) | 3 | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | | |
| occurrences (all) | 2 | | |
| Otitis Externa | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | | |
| occurrences (all) | 0 | | |
| Rhinitis | | | |

| | | | |
|--|---------------------|--|--|
| subjects affected / exposed occurrences (all) | 0 / 5 (0.00%) 0 | | |
| Upper Respiratory Tract Infection subjects affected / exposed occurrences (all) | 1 / 5 (20.00%) 1 | | |
| Metabolism and nutrition disorders Type 1 Diabetes Mellitus subjects affected / exposed occurrences (all) | 1 / 5 (20.00%) 1 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---------------|--|
| 12 April 2019 | Amendment 2 had the following key changes: This sample size no longer supported the stratification on HbA1c and the population PK modeling or PK/PD analysis that was planned, which had been removed from the protocol. A change in randomization ratio from 2:1 to 6:1 (active:placebo) provided a more customary proportion of subjects on active drug to assess safety and allowed for improved recruitment, and had a higher proportion of subjects exposed to active treatment. Due to the reduced number of study subjects, the number of database locks (DBLs) had been reduced to one final DBL at Week 52. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Sample size of 5 subjects in golimumab treatment and 3 in placebo group. For safety (5 on treatment), the limitation gives early read of safety of golimumab in younger population; also makes it not possible to draw conclusions on metabolic assessments.

Notes: